FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

2001 March 24–28, New Orleans, LA
2002 April 6–10, San Francisco, CA
2003 April 26–30, Philadelphia, PA

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org/confrnc.html).

CYTOKINES AND CANCER: REGULATION, ANGIogenesis, AND CLINical APPLICATIONs
September 20–24, 2000
Vail Cascade Hotel & Club, Vail, CO

Chairpersons
Janice P. Dutcher, Bronx, NY
Michael Lotze, Pittsburgh, PA
Giorgio Trinchieri, Dardilly, France

ANGIOGENESIS AND CANCER: FROM BASIC MECHANISMS TO THERAPEUTIC APPLICATIONS
October 11–15, 2000
Grand Traverse Resort, Traverse City, MI

Chairpersons
Judah Folkman, Boston, MA
David A. Cheresh, La Jolla, CA

NEW TARGETS FOR CANCER INTERVENTION
(Joint Conference with the Israel Cancer Association)
November 12–15, 2000
Royal Beach Hotel, Eliat, Israel

Chairpersons
Webster K. Cavenee, La Jolla, CA
Pnina Fishman, Petah Tikva, Israel

MOUSE MODELS OF CANCER
November 29–December 3, 2000
Hyatt Regency La Jolla, La Jolla, CA

Chairpersons
Tyler Jacks, Cambridge, MA
Ronald A. DePinho, Boston, MA

MOLECULAR BIOLOGY AND NEW THERAPEUTIC STRATEGIES: CANCER RESEARCH IN THE 21ST CENTURY
(5th Joint Conference with the Japanese Cancer Association)
February 12–16, 2001
Maui Marriott Resort, Maui, HI

Chairpersons
Webster K. Cavenee, La Jolla, CA
Setsuo Hirohashi, Tokyo, Japan

CANCER SUSCEPTIBILITY GENES AND MOLECULAR CARCINOGENESIS
February 25–March 1, 2001
Hyatt Regency Lake Tahoe, Incline Village, NV

Chairpersons
Allen Balmain, San Francisco, CA
Bruce A.J. Ponder, Cambridge, England

CALANDAR OF EVENTS

Drug Discovery Technology 2000, August 14–17, 2000, The World Trade Center and Seaport Hotel, Boston, MA. Contact: Kristen Langevin, IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01772. Fax: 508.481.4473; E-mail: klangevin@ibcusa.com; Website: www.drugdisc.com.

Fragile Sites, Gene Amplification and Cancer, August 25–26, 2000, Mayo Foundation, Rochester, MN. Contact: David I. Smith, PhD, 200 First Street SW, Rochester, MN 55905. E-mail: thesing.lori@mayo.edu; Website: www.mayo.edu/cme.

7th European Workshop on Pituitary Adenomas, September 10–13, 2000, Oxford, United Kingdom. Contact: Janet Crompton, 29 North Road, St. Andrews, Bristol BS6 5AD, United Kingdom. Phone: (44) 117 924 8160; Fax: (44) 117 924 1208; Email: janetcrompton@compuserve.com.

Frontiers of Cellular Microbiology and Cell Biology: EuroConference on Signaling and Cytoskeleton Plasticity, October 7–12, 2000, Giens, France. Contact: Dr. J. Hendekovic, European Science Foundation, 1 quai Lezay-Marnesia, 67080 Strasbourg Cedex, France. Phone: 33.388.76.71.33; Fax: 33.388.36.69.87; E-mail: euresco@esf.org; Website: http://www.esf.org.euresco.

Eleventh Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, October 12–14, 2000, Princeton, NJ. Abstract Deadline: May 1, 2000. Contact: Lois Gillespie, Garden State Cancer Center, 520 Belleville Ave., Belleville, NJ 07109. Fax: 973-844-7020; E-mail: gscancer@att.net.

Cancer Therapy for the New Millennium. October 12–14, 2000, Palermo, Italy. Contact: Center for Bio-Medical Communication, Inc., 433 Hackensack, NJ 07601. Phone: (201) 342-5300; Fax: (201) 342-7555; E-mail: cmeinfo@cbcbiomed.com; Website: www.cbcbiomed.com.

20th Annual Nurses Cancer Symposium, October 16–18, 2000, La Jolla Marriott, La Jolla, CA. Contact: Ruthanne Crawford, Stevens Cancer Center, 9888 Genesee Avenue, La Jolla, CA 92037. Phone: 858.626.6794; Fax: 858.626.6793; E-mail: crawford.ruthanne@scrippshealth.org.

2nd International Conference on Tumor Microenvironment, Progression, Therapy & Prevention, October 29–November 1, 2000, Tiberias, Israel. Contact: The Secretariat, 2nd International Conference on Tumor Microenvironment,
ANNOUNCEMENTS

Progression, Therapy & Prevention, P.O. Box 50006, Tel Aviv, Israel. Phone: 972.3.5140000; Fax: 972.3.5140077; E-mail: tumormicro@kenes.com.

Hong Kong Academy of Medicine Second International Congress, November 2–5, 2000, Hong Kong Academy of Medicine, Hong Kong. Contact: Congress Secretariat, 10/F, Hong Kong Academy of Medicine Jockey Club Building, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong. Phone: (852) 2871 8787; Fax: (852) 2871 8989.

First International Symposium on Translational Research in Breast and Ovarian Cancers, November 3–5, 2000, Four Seasons Hotel Dublin, Dublin, Ireland. Contact: Kim Pearson, The CBCE/S.G. Madison, Dallas, TX. Phone: 972.929.1900 x 104; Fax: 972.929.1901; E-mail: kimp@sgmadison.com.

ONS Institutes of Learning, November 3–5, 2000, Charlotte Convention Center, Charlotte, NC. Contact: Oncology Nursing Society, 501 Holiday Drive, Pittsburgh, PA 15220-2749. Phone: 412.921.7373; Fax: 412.921.6565; E-mail: customer.service@ons.org.


Seventh Hong Kong International Cancer Congress, December 7–9, 2000, Hong Kong Academy of Medicine, Hong Kong. Contact: 7th HKICC Congress Secretariat, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong. Phone: (852) 2818-0232 / (852) 2855-4235; Fax: (852) 2818-1186; E-mail: mededcon@hku.hk.


Glioma: Frome Gene to Cure, April 26–28, 2001, Amsterdam, The Netherlands. Contact: European Cancer Centre, P.O. Box 9236, NL-1006 AE Amsterdam, The Netherlands. Phone: 31.0.20.346.2547; Fax: 31.0.20.346.2525; E-mail: ecc@ikca.nl; Website: http://www.EurCanCen.org.

4th International Gastric Cancer Congress sponsored by The International Gastric Cancer Association and Memorial Sloan Kettering Cancer Center, April 30–May 2, 2001, New York Hilton, New York, N.Y. Contact: Jan Sharkey at (e-mail) jsharkey@slackinc.com or (website) www.mskcc.org/igcc2001.

9th Asian Pacific Congress of Clinical Biochemistry, November 11–16, 2001, Ashok Hotel, New Delhi, India. Fax: 91.11.6011543; E-mail: cms@de13.vsnl.net.in.
Corrections

In the article by A. Eberhard et al., entitled “Heterogeneity of Angiogenesis and Blood Vessel Maturation in Human Tumors: Implications for Antiangiogenic Tumor Therapies,” which appeared in the March 1, 2000 issue of Cancer Research (pp. 1388–1393), Figure 2, panel A appeared incorrectly.

Microvessel density (MVD) counts are mostly expressed as number of microvessels per microscopic field of view. At the request of one of the reviewers, we expressed MVD counts in absolute units as number/mm². When transforming MVD counts to absolute units, we inadvertently miscalculated the area of a microscopic high power field of view as 0.0681 mm² as stated in the “Materials and Methods” section of our article. Given that a microscopic high power field of view reflects a surface area of 0.196 mm², absolute microvessel densities as shown in Fig. 2A were overestimated by a factor of 2.88. This mistake affects the absolute number of microvessels/mm². It does not affect any of the other results of the study or any of the study’s conclusions. We apologize for this mistake. The correct Figure 2 and corresponding legend appear below.

Erratum

In the article by H. Fukazawa and Y. Uehara, entitled “U0126 Reverses Ki-ras-mediated Transformation by Blocking Both Mitogen-activated Protein Kinase and p70 S6 Kinase Pathways,” which appeared in the April 15, 2000 issue of Cancer Research (pp. 2104–2107), the first sentence of the Abstract appeared incorrectly as: “U0126, a recently introduced mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase inhibitor reversed morphology and inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts.” The correct sentence should read: “U0126, a recently introduced mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase inhibitor reversed morphology and inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts.”
Correction for vol. 59, p. 5815

Cancer Res 2000;60:3668.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/13/3668.1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/60/13/3668.1. Click on “Request Permissions” which will take you to the Copyright Clearance Center's (CCC) Rightslink site.